Company registration number 02758923 (England and Wales)
OAKLEIGH GROUP OF PHARMACIES LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 OCTOBER 2025
PAGES FOR FILING WITH REGISTRAR
OAKLEIGH GROUP OF PHARMACIES LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 8
OAKLEIGH GROUP OF PHARMACIES LIMITED
BALANCE SHEET
AS AT 31 OCTOBER 2025
31 October 2025
- 1 -
31 October 2025
31 March 2025
Notes
£
£
£
£
Fixed assets
Intangible assets
3
478,104
541,250
Tangible assets
4
232,620
125,234
710,724
666,484
Current assets
Stocks
129,354
130,641
Debtors
5
7,635,583
6,820,194
Cash at bank and in hand
483,646
628,204
8,248,583
7,579,039
Creditors: amounts falling due within one year
6
(701,812)
(468,215)
Net current assets
7,546,771
7,110,824
Total assets less current liabilities
8,257,495
7,777,308
Creditors: amounts falling due after more than one year
7
(4,167)
Provisions for liabilities
(16,092)
(19,998)
Net assets
8,241,403
7,753,143
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
8,241,303
7,753,043
Total equity
8,241,403
7,753,143
OAKLEIGH GROUP OF PHARMACIES LIMITED
BALANCE SHEET (CONTINUED)
AS AT 31 OCTOBER 2025
31 October 2025
- 2 -
For the financial period ended 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true
The financial statements were approved by the board of directors and authorised for issue on 8 September 2026 and are signed on its behalf by:
Mrs A Patel
Mr A Patel
Director
Director
Company registration number 02758923 (England and Wales)
OAKLEIGH GROUP OF PHARMACIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 OCTOBER 2025
- 3 -
1
Accounting policies
Company information
Oakleigh Group Of Pharmacies Limited is a private company limited by shares incorporated in England and Wales. The registered office is Elthorne Gate, 64 High Street, Pinner, Middlesex, HA5 5QA.
1.1
Reporting period
These financial statements have been prepared for the seven-month period ended 31 October 2025. During the period, the company changed its accounting reference date from 31 March to 31 October to provide consistency in financial reporting periods across other group companies.
Additionally, the comparative amounts relate to a twelve month period and are not directly comparable with those for the current period.
1.2
Basis of preparation
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
1.3
Going concern
Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.
1.4
Revenue
Turnover represents revenue generated from the pharmacy and is recognised at the fair value of the consideration
received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discount, settlement discounts and volume rebates.
1.5
Intangible fixed assets - goodwill
Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 20 years.
For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.
OAKLEIGH GROUP OF PHARMACIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
- 4 -
1.6
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Fixtures and fittings
25% on cost
Computers
25% on cost
Motor vehicles
25% on cost
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
1.7
Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.
Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.
1.8
Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
1.9
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
OAKLEIGH GROUP OF PHARMACIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
- 5 -
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
1.10
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
1.11
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
1.12
Leases
As lessor
When the company acts as a lessor, a lease is classified as a finance lease whenever it transfers substantially all the risks and rewards of ownership of the underlying asset to the lessee, either at the end of the lease term or for the major part of the economic life of the asset. All other leases are classified as operating leases. If an arrangement contains both lease and non-lease components, the company allocates the consideration in the contract to the two elements.
Rental income from operating leases is recognised on a straight line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised on a straight line basis over the lease term.
1.13
Government grants
Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.
A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.
1.14
The company has taken advantage of the exemption, under the terms of Financial Reporting Standard 102,' The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.
OAKLEIGH GROUP OF PHARMACIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 OCTOBER 2025
- 6 -
2
Employees
The average monthly number of persons (including directors) employed by the company during the period was:
2025
2025
Number
Number
Total
17
17
3
Intangible fixed assets
Goodwill
£
Cost
At 1 April 2025 and 31 October 2025
2,327,509
Amortisation and impairment
At 1 April 2025
1,786,259
Amortisation charged for the period
63,146
At 31 October 2025
1,849,405
Carrying amount
At 31 October 2025
478,104
At 31 March 2025
541,250
4
Tangible fixed assets
Fixtures and fittings
Computers
Motor vehicles
Total
£
£
£
£
Cost
At 1 April 2025
356,657
9,925
46,245
412,827
Additions
144,940
1,350
146,290
Disposals
(31,250)
(31,250)
At 31 October 2025
501,597
11,275
14,995
527,867
Depreciation and impairment
At 1 April 2025
250,331
8,517
28,745
287,593
Depreciation charged in the period
20,918
487
1,874
23,279
Eliminated in respect of disposals
(15,625)
(15,625)
At 31 October 2025
271,249
9,004
14,994
295,247
OAKLEIGH GROUP OF PHARMACIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 OCTOBER 2025
4
Tangible fixed assets
Fixtures and fittings
Computers
Motor vehicles
Total
£
£
£
£
(Continued)
- 7 -
Carrying amount
At 31 October 2025
230,348
2,271
1
232,620
At 31 March 2025
106,326
1,408
17,500
125,234
5
Debtors
2025
2025
Amounts falling due within one year:
£
£
Trade debtors
402,380
222,928
Amounts owed by group undertakings
5,779,084
5,325,383
Other debtors
1,435,605
1,243,706
Prepayments and accrued income
18,514
28,177
7,635,583
6,820,194
6
Creditors: amounts falling due within one year
2025
2025
£
£
Bank loans
6,667
8,333
Trade creditors
377,828
358,797
Taxation and social security
128,872
(48,315)
Other creditors
188,445
149,400
701,812
468,215
7
Creditors: amounts falling due after more than one year
2025
2025
Notes
£
£
Bank loans and overdrafts
4,167
The bank loans payable within and after one year are secured by way of fixed and floating charge over the assets in the
company.
8
Related party transactions
Transactions with related parties
During the period the company entered into the following transactions with related parties:
OAKLEIGH GROUP OF PHARMACIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 OCTOBER 2025
8
Related party transactions
(Continued)
- 8 -
Management fees received
2025
2025
£
£
Entities with common controlling shareholders and directors
73,015
91,192
The above income represents management fees receivable in respect of staff costs recharged to companies under the control of a director.
2025
2025
Amounts due from related parties
£
£
Entities with common controlling shareholders and directors
1,169,649
1,193,753
The above disclosed amount is included within the other debtors due in one year. The loan is unsecured, interest free and repayable on demand.
9
Parent company
The ultimate controlling party is Wellcare Group Ltd who owns 100% of the issued share capital.
2025-10-312025-04-01falsefalsefalse08 September 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityMiss A PatelMr A Patel027589232025-04-012025-10-31027589232025-10-31027589232025-03-3102758923core:Goodwill2025-10-3102758923core:Goodwill2025-03-3102758923core:FurnitureFittings2025-10-3102758923core:ComputerEquipment2025-10-3102758923core:MotorVehicles2025-10-3102758923core:FurnitureFittings2025-03-3102758923core:ComputerEquipment2025-03-3102758923core:MotorVehicles2025-03-3102758923core:CurrentFinancialInstrumentscore:WithinOneYear2025-10-3102758923core:CurrentFinancialInstrumentscore:WithinOneYear2025-03-3102758923core:Non-currentFinancialInstrumentscore:AfterOneYear2025-10-3102758923core:Non-currentFinancialInstrumentscore:AfterOneYear2025-03-3102758923core:CurrentFinancialInstruments2025-10-3102758923core:CurrentFinancialInstruments2025-03-3102758923core:ShareCapital2025-10-3102758923core:ShareCapital2025-03-3102758923core:RetainedEarningsAccumulatedLosses2025-10-3102758923core:RetainedEarningsAccumulatedLosses2025-03-3102758923bus:Director12025-04-012025-10-3102758923bus:Director22025-04-012025-10-3102758923core:Goodwill2025-04-012025-10-3102758923core:FurnitureFittings2025-04-012025-10-3102758923core:ComputerEquipment2025-04-012025-10-3102758923core:MotorVehicles2025-04-012025-10-31027589232024-04-012025-03-3102758923core:Goodwill2025-03-3102758923core:FurnitureFittings2025-03-3102758923core:ComputerEquipment2025-03-3102758923core:MotorVehicles2025-03-31027589232025-03-3102758923core:Non-currentFinancialInstruments2025-10-3102758923core:Non-currentFinancialInstruments2025-03-3102758923bus:PrivateLimitedCompanyLtd2025-04-012025-10-3102758923bus:SmallCompaniesRegimeForAccounts2025-04-012025-10-3102758923bus:FRS1022025-04-012025-10-3102758923bus:AuditExemptWithAccountantsReport2025-04-012025-10-3102758923bus:FullAccounts2025-04-012025-10-31xbrli:purexbrli:sharesiso4217:GBP